Scottish Enterprise

"Following on from our successful seed funding round from Gabriel Investments and Equity Gap, Series A is an important milestone in our global growth plans, as we seek to improve health outcomes for animals through earlier disease diagnosis using revolutionary biomarker technology and artificial intelligence. The geographical spread of this investment round reflects the global opportunity for MI:RNA to deploy our platform for better outcomes for pets."

"We are in the midst of the second space race with rocket developers on the cusp of launching from UK soil, with the number of launches across the globe growing exponentially."

"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."

"In the UK tech sector, the investment climate has been both unpredictable and incredibly challenging for the past two years. Despite this, Phlo’s investors have provided the leadership team with a huge vote of confidence in our business model and product ecosystem. This gives additional significance to the close of this fresh investment round, which will unlock huge business and growth opportunities across the entire Phlo network. I’d like to thank Par Equity, Thairm Bio and Scottish Enterprise for their support and belief in Phlo’s vision for the future of healthcare."

"I am delighted and honoured to be taking on the chairmanship for Bright Ascension at this very exciting point in time and looking forward to helping steer the company towards a very successful future"